Jump to content

Significant Benefits In Non-small-cell Lung Cancer


RandyW

Recommended Posts

Significant Benefits In Non-small-cell Lung Cancer From Customizing Erlotinib Treatment

ScienceDaily (Sep. 15, 2008) — Lung cancer patients whose tumors carry specific genetic mutations can achieve significantly longer survival when treated with targeted therapies such as erlotinib, Spanish researchers report.

Investigators from the Spanish Lung Cancer Group conducted the largest-ever study to examine the benefits of customizing lung cancer treatment based on mutations in the epidermal growth factor receptor (EGFR) gene.

At the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm they report that patients with the mutations survived for almost two years on average when treated with erlotinib.

“For the first time in lung cancer management, doctors are able, by testing EGFR mutations, to identify a subgroup of patients (between 15-22% according to our experience) who can obtain a new survival landmark in advanced non-small-cell lung cancer, with oral EGFR inhibitors like erlotinib,” said Prof. Rafael Rosell, who presented the new data at the meeting.

The Spanish group took tumor biopsies from 2,312 patients with advanced non-small-cell lung cancer and screened them for two common mutations in the gene for epidermal growth factor receptor, which can be a cause of lung cancer.

The two mutations they screened for were a deletion in exon 19 of the receptor’s tyrosine kinase domain, and a mutation in exon 21. Tumors with EGFR mutations are more frequently seen in people who have never smoked and in women.

The group identified 307 patients who carried the EGFR mutations. Each was treated with erlotinib.

Based on data from 193 patients, the mean survival was 22 months, Prof. Rosell reported. For women, the mean survival was 28 months; for men, 17 months. Mean time to progression was 12 months overall, and was longer in women than in men.

The researchers saw a response to treatment in 71% of patients, including 24 patients who experienced a complete response. The probability of response was twice as high in patients aged 61-71 years and in patients with the exon 19 deletion.

“Therefore non-small-cell lung cancers with EGFR mutations display a two-to-three-fold increment in outcome in comparison with non-small-cell lung cancers treated with chemotherapy, in which median survival is 11 months, time-to-progression is 5 months, and response 20-30%,” Prof. Rosell said.

“These results are a new clinical discovery. The impressive survival and response are undeniable. This is a new landmark of treatment in non-small-cell lung cancer, and the first tangible target for customizing treatment with EGFR tyrosine kinase inhibitors.”

--------------------------------------------------------------------------------

Adapted from materials provided by European Society for Medical Oncology (ESMO), via AlphaGalileo.

Need to cite this story in your essay, paper, or report? Use one of the following formats:

APA

MLA European Society for Medical Oncology (ESMO) (2008, September 15). Significant Benefits In Non-small-cell Lung Cancer From Customizing Erlotinib Treatment. ScienceDaily. Retrieved September 16, 2008, from http://www.sciencedaily.com­ /releases/2008/09/080915083729.htm

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...

Important Information

By using this site, you agree to our Terms of Use.